Soluble CD14 levels, interleukin 6, and mortality among prevalent hemodialysis patients.
about
Alkaline phosphatase: a novel treatment target for cardiovascular disease in CKD.Role of the Gut Microbiome in Uremia: A Potential Therapeutic Target.Synthesis and biological evaluation of novel indole-2-one and 7-aza-2-oxindole derivatives as anti-inflammatory agents.The Th17/Treg ratio, IL-1RA and sCD14 levels in primary HIV infection predict the T-cell activation set point in the absence of systemic microbial translocation.Protein-energy wasting and mortality in chronic kidney disease.The gut microbiome, kidney disease, and targeted interventions.Serum Trimethylamine-N-Oxide Is Strongly Related to Renal Function and Predicts Outcome in Chronic Kidney DiseaseEffect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients.Associations of Soluble CD14 and Endotoxin with Mortality, Cardiovascular Disease, and Progression of Kidney Disease among Patients with CKD.Is Endotoxemia in Stable Hemodialysis Patients an Artefact? Limitations of the Limulus Amebocyte Lysate Assay and Role of (1→3)-β-D Glucan.HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation.Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC.Lack of effect of the CD14 promoter gene C-159T polymorphism on nutritional status parameters in hemodialysis patients.Uremic plasma impairs barrier function and depletes the tight junction protein constituents of intestinal epithelium.Association of soluble endotoxin receptor CD14 and mortality among patients undergoing hemodialysis.CKD impairs barrier function and alters microbial flora of the intestine: a major link to inflammation and uremic toxicity.A comparative study of blood endotoxin detection in haemodialysis patientsThe immunoregulatory function of vitamin D: implications in chronic kidney disease.Endotoxemia in end-stage kidney disease.Altered intestinal microbial flora and impaired epithelial barrier structure and function in CKD: the nature, mechanisms, consequences and potential treatment.Intestinal Barrier Disturbances in Haemodialysis Patients: Mechanisms, Consequences, and Therapeutic Options.Inflammation and premature aging in advanced chronic kidney disease.Disintegration of colonic epithelial tight junction in uremia: a likely cause of CKD-associated inflammation.Soluble CD14 and fracture risk.Mode of renal replacement therapy determines endotoxemia and neutrophil dysfunction in chronic kidney disease.Endotoxin binding by sevelamer: potential impact on nutritional status.European Training and Research in Peritoneal Dialysis: scientific objectives, training, implementation and impact of the programme.Structural and functional differences in gut microbiome composition in patients undergoing haemodialysis or peritoneal dialysis.The Chronic Kidney Disease - Colonic Axis.Targeting Immunity in End-Stage Renal Disease.Circulating Bacterial Fragments as Cardiovascular Risk Factors in CKD.Changes in the inflammatory and oxidative stress markers during a single hemodialysis session in patients with chronic kidney disease
P2860
Q30234466-35D6E173-A79F-49E4-BF91-F6CAFCC0DE12Q33613115-9A6BDB70-DDD1-41E1-B846-B5D6D461302EQ34394336-25FDE124-B3BF-4619-A99B-305F1EA4329BQ34789326-DE2BCCF9-FD86-4A53-9E7F-D4890C232348Q35024794-BF3B3ACF-61F3-4BA8-B82F-2891440BFE9DQ35042986-3B1AC9FC-EAB8-40FD-8D35-BA45939D2168Q35889821-6F42B836-161B-415A-8278-8DC66F37F8F3Q35983529-12C1F20C-96E5-4ADF-B4ED-87AFDD300CBEQ36025615-682D963B-DDD3-4A1B-835A-C014A740D416Q36169427-EEDAA274-7B7E-4E49-90B8-18B7D8C8402FQ36383621-F2C6A81F-AF49-435C-9CEA-F04A8BB63188Q36443224-B0B42859-DECB-4E01-97E5-8C0F8B043CADQ36473805-F8D8E412-C914-472A-B72D-9D0C9B20C79CQ37050237-FD196063-8629-4B44-8324-9D8D45F8138EQ37079653-4F2FDD66-7D2C-4432-9D00-1812A0F33396Q37131182-D44BF2F3-086B-4F93-B651-B58560C5CB6FQ37139884-8FBF77AC-D067-43EB-81E6-7AA1ABA09BE2Q38012025-53773441-7207-4429-A004-0C35C3D634C8Q38231473-68C537B0-5EFA-4BDA-9DC2-185394C19F05Q38425357-6C1C9401-4CBF-4B16-BD4A-0CECAA028F9AQ38757951-8EF2BCDB-8442-4B39-8F8F-62E5171CEFB8Q39309490-17C00F31-5002-4E88-9FCD-FCE3B1E1AA53Q39598955-27B8B548-5B00-4D71-B69C-20F122748C4EQ40219806-DFEE8A58-3FEE-4FF8-B0A0-126041534416Q40518328-043B45EC-4CE2-49B0-9D40-E61103F02C55Q42718522-EB43775C-71C6-418F-A92A-FF6421A7EFDEQ44368427-7B04B9DC-B6DD-41E9-8A9E-57082AA76547Q46260769-27140C3F-1EC3-4944-ACB1-DAC08E050F49Q46415279-EED4E0AB-11DD-414A-8327-2E90783BFF74Q50872135-26F362FF-9746-4223-B665-20C756029F7DQ54233821-18B639DD-07B1-4FFB-BC11-F12251C33B84Q57025025-AF18A37B-CC3A-4E17-A415-C9F01BAB386E
P2860
Soluble CD14 levels, interleukin 6, and mortality among prevalent hemodialysis patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Soluble CD14 levels, interleukin 6, and mortality among prevalent hemodialysis patients.
@en
Soluble CD14 levels, interleukin 6, and mortality among prevalent hemodialysis patients.
@nl
type
label
Soluble CD14 levels, interleukin 6, and mortality among prevalent hemodialysis patients.
@en
Soluble CD14 levels, interleukin 6, and mortality among prevalent hemodialysis patients.
@nl
prefLabel
Soluble CD14 levels, interleukin 6, and mortality among prevalent hemodialysis patients.
@en
Soluble CD14 levels, interleukin 6, and mortality among prevalent hemodialysis patients.
@nl
P2093
P2860
P50
P1476
Soluble CD14 levels, interleukin 6, and mortality among prevalent hemodialysis patients
@en
P2093
Dominic S C Raj
Jennet Ferguson
Olof Heimbürger
Pope L Moseley
Vallabh O Shah
P2860
P304
P356
10.1053/J.AJKD.2009.06.022
P577
2009-09-06T00:00:00Z